| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5927704 | American Heart Journal | 2015 | 6 Pages |
Abstract
The excess in thrombotic and bleeding events in the apixaban group after study drug discontinuation appears to be related to an increased risk associated with the initiation of a VKA rather than a direct effect of apixaban. Whether â¥2 days of apixaban bridging improves outcomes during VKA transition is unknown and deserves further evaluation.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Christopher B. MD, Renato D. MD, PhD, Michael MD, Jack MD, Elaine M. MD, MPH, John H. MD, MHS, Laine PhD, Junyuan PhD, M. Cecilia MD, Freek MD, PhD, Jack MD, Denis MD, Lars MD, PhD,